BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

QNRX upcoming catalysts

Quoin Pharmaceuticals: 3 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 0 FDA event(s). Subscribe to QNRX (.ics).

Drugs: QRX003, 4% Lotion, QRX003

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-30 est.P2/P3Quoin Pharmaceuticals QNRXNCT05789056 Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromeNetherton Syndromerecruiting20
2026-12-30 est.P2/P3Quoin Pharmaceuticals QNRXNCT06953466 Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeNetherton Syndromerecruiting8
2027-01-31 est.P2/P3Quoin Pharmaceuticals QNRXNCT07538583 Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeNetherton Syndromerecruiting16

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-12-30P2/P3Quoin Pharmaceuticals QNRXNCT05521438 Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromeNetherton Syndromeactive not recruiting30

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.